ALB and cerebral infarction: In conclusion, our study suggests that the serum albumin-to-creatinine ratio (sACR) may serve as a novel and accessible biomarker for identifying individuals at increased risk of silent cerebral infarction (SCI) and subsequent adverse cerebrovascular events.